Sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability
Both medications serve different purposes, and when used correctly, they can help improve your health
Patient-Centered Care We provide a patient-centered approach that emphasizes collaboration, education, and empowerment to enhance our patients overall experience, satisfaction, and results
For very precise low-dose measurements, a 50-unit (0.5 mL) or 30-unit (0.3 mL) syringe provides finer graduation marks
Californias Insurance Landscape for GLP-1s California Medicaid, known as Medi-Cal, has expanded GLP-1 coverage in recent years, but coverage for weight loss specifically (as opposed to type 2 diabetes) remains inconsistent
Every tirzepatide journey is unique, and several factors shape results